Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$30.11 +0.8%	$28.69	$23.23 ▼ $42.29	$960.10M	0.63	403,539 shs	225,794 shs
ELVN Enliven Therapeutics	$21.16 +4.3%	$18.94	$13.30 ▼ $30.03	$995.61M	0.79	293,740 shs	645,327 shs
FHTX Foghorn Therapeutics	$4.87 -0.4%	$4.30	$2.94 ▼ $10.25	$272.58M	3.04	143,062 shs	82,827 shs
XFOR X4 Pharmaceuticals	$2.30 -5.0%	$3.73	$2.26 ▼ $30.90	$14.01M	0.67	124,479 shs	396,741 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	+0.17%	+0.57%	+3.53%	-0.90%	-5.68%
ELVN Enliven Therapeutics	-4.74%	-12.13%	+23.72%	-4.83%	-5.36%
FHTX Foghorn Therapeutics	+3.60%	+11.39%	+18.12%	+23.17%	-7.74%
XFOR X4 Pharmaceuticals	-9.36%	-11.36%	-21.94%	-68.90%	-92.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	3.6988 of 5 stars	3.4	1.0	3.0	1.5	0.8	1.9
ELVN Enliven Therapeutics	2.6581 of 5 stars	3.5	1.0	0.0	3.0	4.2	0.0
FHTX Foghorn Therapeutics	1.7469 of 5 stars	3.6	2.0	0.0	0.0	1.7	0.6
XFOR X4 Pharmaceuticals	4.6543 of 5 stars	3.5	2.0	4.6	1.1	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	45.30% Upside
ELVN Enliven Therapeutics	3.00	Buy	$39.60	87.15% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	148.97% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$72.33	3,044.93% Upside

Current Analyst Ratings Breakdown

Latest FHTX, XFOR, ELVN, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/2/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $7.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.53	$12.44 per share	2.42	$7.10 per share	4.24
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	12.01	N/A	N/A	($0.82) per share	-5.94
XFOR X4 Pharmaceuticals	$2.56M	5.20	N/A	N/A	$3.90 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.68	5.00	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$37.45M	$2.14	1.07	N/A	N/A	46.54%	-181.56%	-54.36%	8/6/2025 (Estimated)

Latest FHTX, XFOR, ELVN, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/1/2025	Q1 2025	XFOR X4 Pharmaceuticals	-$4.13	$0.04	+$4.17	$0.04	$7.03 million	$28.81 million
3/25/2025	Q4 2024	XFOR X4 Pharmaceuticals	-$5.10	-$6.00	-$0.90	-$0.20	$1.07 million	$1.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.30	1.08	1.01
ELVN Enliven Therapeutics	N/A	21.07	21.06
FHTX Foghorn Therapeutics	N/A	3.16	3.16
XFOR X4 Pharmaceuticals	3.30	3.70	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
ELVN Enliven Therapeutics	95.08%
FHTX Foghorn Therapeutics	61.55%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
ELVN Enliven Therapeutics	25.90%
FHTX Foghorn Therapeutics	7.58%
XFOR X4 Pharmaceuticals	2.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
XFOR X4 Pharmaceuticals	80	5.79 million	5.67 million	Optionable

FHTX, XFOR, ELVN, and COLL Headlines

Recent News About These Companies

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025 | globenewswire.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA Congress

May 16, 2025 | nasdaq.com

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025 | globenewswire.com

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

May 2, 2025 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript

May 2, 2025 | insidermonkey.com

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025 | seekingalpha.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | finance.yahoo.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | globenewswire.com

X4 Pharmaceuticals Q1 2025 Earnings Preview

April 30, 2025 | msn.com

X4 Pharmaceuticals Analyst Ratings

April 30, 2025 | benzinga.com

Earnings Preview For X4 Pharmaceuticals

April 30, 2025 | benzinga.com

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

April 30, 2025 | insidermonkey.com

X4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28

April 26, 2025 | nasdaq.com

X4 Pharmaceuticals trading halted, news pending

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals announces 1-for-30 reverse stock split

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals to conduct reverse stock split

April 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, XFOR, ELVN, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$30.11 +0.23 (+0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$30.10 -0.02 (-0.05%)

As of 05:40 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics NASDAQ:ELVN

$21.16 +0.87 (+4.29%)

Closing price 04:00 PM Eastern

Extended Trading

$21.15 -0.01 (-0.05%)

As of 04:38 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Foghorn Therapeutics NASDAQ:FHTX

$4.87 -0.02 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$4.92 +0.05 (+1.03%)

As of 07:52 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

X4 Pharmaceuticals NASDAQ:XFOR

$2.30 -0.12 (-4.96%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 +0.03 (+1.09%)

As of 07:59 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time